EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Complicated Staphylococcus aureus Bacteremia Receiving Standard-of-Care Antibiotics

Loren G Miller iD, Vance G Fowler, Jose M Miro iD, Juan Pablo Horcajada, Nicholas Lewin-Koh, Tom Chu, Sharon Rymut, Johnny Gutierrez, Carrie M Rosenberger, Wouter L W Hazenbos, Sara Glickstein, Jessica A Couch iD und 1 weitere

Open Forum Infectious Diseases · 29.09.2026 · 13 (10)

DOI: 10.1093/ofid/ofag608 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 26.09.2026. Verfasst von Loren G Miller und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, and Harbor-UCLA Medical Center, Torranc…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Safe and effective therapies are needed for hospitalized patients with complicated Staphylococcus aureus infections, including approaches capable of eradicating intracellular bacterial reservoirs that contribute to treatment failure. This study evaluated the safety, tolerability, and pharmacokinetics of DSTA4637S, an antibody–antibiotic conjugate combining an anti-S. aureus antibody with a rifamycin-class antibiotic, in patients with complicated S. aureus bacteremia.

Methods

In this phase 1b, randomized, double-blind, placebo-controlled study, 25 patients with methicillin-sensitive (MSSA, 68%) or -resistant (MRSA, 32%) complicated S. aureus bacteremia received weekly intravenous doses of DSTA4637S at 15, 45, or 100 mg/kg in combination with at least 4 weeks of standard-of-care antistaphylococcal antibiotics.

Results

Most patients (92%) experienced ≥1 treatment-emergent adverse event (TEAE), of which 44% were considered treatment-related. Grade ≥3 TEAEs and serious adverse events occurred in 72% and 56% of patients, respectively. The most common grade ≥3 TEAEs were infusion-related reactions (IRRs), pneumonia, anemia, and respiratory failure. Four patients (21%) receiving DSTA4637S discontinued study treatment due to treatment-related IRRs. Systemic exposure of DSTA4637S in patients increased approximately dose-proportionally from 15 to 100 mg/kg but was 30%–60% lower than previously observed in healthy volunteers.

Conclusions

The safety profile of DSTA4637S, characterized by unpredictable IRRs, and its pharmacokinetic behavior in patients differed substantially from those observed in healthy volunteers, highlighting the critical importance of conducting early phase studies in the target patient population.

Schlagwörter

Stichwörter der Autor:innen

Staphylococcus aureusantibody–antibiotic conjugatebacteremiaclinical trial

Autor:innen und Institutionen

  • Division of Infectious Diseases, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, and Harbor-UCLA Medical Center, Torrance, California, USA.
  • Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
  • Hospital Clinic-IDIBAPS, University of Barcelona, and Reial Academia de Medicina de Catalunya (RAMC), Barcelona, Spain.
  • CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain.

ORCID-Profile: Loren G Miller, Jose M Miro, Jessica A Couch

Förderung

  • Genentech, Inc

Zitieren

APA

Miller, L. G., Fowler, V. G., Miro, J. M., Horcajada, J. P., Lewin-Koh, N., Chu, T., Rymut, S., Gutierrez, J., Rosenberger, C. M., Hazenbos, W. L. W., Glickstein, S., Couch, J. A., & Peck, M. C. (2026). A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Complicated Staphylococcus aureus Bacteremia Receiving Standard-of-Care Antibiotics. Open Forum Infectious Diseases, 13(10). https://doi.org/10.1093/ofid/ofag608

Vancouver

Miller LG, Fowler VG, Miro JM, Horcajada JP, Lewin-Koh N, Chu T, et al. A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Complicated Staphylococcus aureus Bacteremia Receiving Standard-of-Care Antibiotics. Open Forum Infectious Diseases. 2026;13(10). doi:10.1093/ofid/ofag608

BibTeX
@article{Miller2026,
  author = {Miller, Loren G and Fowler, Vance G and Miro, Jose M and Horcajada, Juan Pablo and Lewin-Koh, Nicholas and Chu, Tom and Rymut, Sharon and Gutierrez, Johnny and Rosenberger, Carrie M and Hazenbos, Wouter L W and Glickstein, Sara and Couch, Jessica A and Peck, Melicent C},
  title = {A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Complicated Staphylococcus aureus Bacteremia Receiving Standard-of-Care Antibiotics},
  journal = {Open Forum Infectious Diseases},
  year = {2026},
  volume = {13},
  number = {10},
  doi = {10.1093/ofid/ofag608}
}
Kostenlos starten →